Cumulus Neuroscience Presents Data at AD/PD™ 2024 Annual Meeting

Date
March 12, 2024
Location
London

Data presented at the 2024 Alzheimer’s & Parkinson’s Diseases (AD/PD) Conference provides validation of two novel assessments in the Cumulus Neuroscience platform, suitable for at-home use by patients, in terms of sensitivity to change in cognitive impairment.

BELFAST, Northern Ireland and CAMBRIDGE, Mass.—March 8, 2024— Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented validation data of two novel assessments of cognitive impairment at the AD/PD™ 2024 in Lisbon, Portugal.

“We are excited to share technical validation data for two novel cognitive tasks from a pair of parallel studies. These demonstrated that the tasks are patient-friendly, can be used autonomously to capture high quality data at home and are sensitive to cognitive impairment, making them suitable for use in clinical trials where precision measurement at the individual subject level is a must,” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. “These validated tasks have the potential to enable earlier detection of disease and provide biopharma with longitudinal real-world data that can streamline clinical trial designs.”

Titled “Technical and Clinical Validation of Novel Cognitive Tests for Remote Sampling of Memory and Executive Function,” the poster features data demonstrating that the Cumulus Neuroassessment platform’s “Symbol Swap” (a symbol-coding task, related to the classic DSST) and “Memory Match” (a visual associative learning paradigm, designed to test recollection memory) can be frequently and accurately used by patients living with mild to moderate AD to measure for cognitive impairment.

In the parallel studies, Symbol Swap and Memory Match underwent technical validation in an alcohol challenge lab study (n=30), assessing sensitivity to subtle sedation and cognitive impairment, and were also deployed in a longitudinal field study of people living with mild AD dementia (n=59) and matched healthy control participants (n=60). In the patient study, both tasks strongly differentiated AD status with equivalent or greater sensitivity than the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog), which is the standard primary outcome neuropsychological measure for AD trials.

“We need to find new ways to catch Alzheimer’s disease earlier, and we need a paradigm shift overall in the diagnosis, treatment and care of the condition,” said Aman Bhatti, MD, CEO, Cumulus. “These data demonstrate a promising and exciting step toward that goal, by validating two novel cognitive tasks that are easy for patients to use and sensitive to impairment. These tasks, as part of the Cumulus Neuroassessment Platform, are ideal for modern clinical trials requiring individual-level precision measurement, and our hope is that this important technology will help researchers to better understand disease progression and early symptoms of AD, so that we can improve diagnosis and treatment for the millions of individuals and families impacted.”

Cumulus continues to advance its EEG headset and data platform, providing biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions. To learn more, visit www.cumulusneuro.com.

Notes to Editors

Alzheimer’s is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, mood swings, changes in behavior and personality, and difficulty with language and communication. Currently, there is no known cure for Alzheimer’s. Today, earlier diagnosis can enable patients to make lifestyle changes, including exercising and decreasing alcohol consumption, both of which have been shown to slow disease progression. In the future, having the ability to diagnose patients earlier may expedite enrollment in clinical studies and the identification of new treatments.

With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralised trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.

Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient’s home – all with a FDA 510(k) cleared and UKCA marked EEG Headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.

The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.